Chimeric antigen receptor (CAR) T-cell therapy of glioblastoma has limited success due, in part, to two issues: Antigen escape through a molecular change and metabolic exhaustion of the CAR T-cells due to nutrient insufficiency in the glioblastoma microenvironment. To overcome these obstacles, the researchers will develop bi-specific and metabolically superior CAR T cells that will target two different molecules, and which will be genetically programmed to overcome glucose and oxygen insufficiency. The study is expected to provide a novel approach and practical tools for precision therapy of glioblastomas, and therefore is crucial for the transitioning of CAR T-cells from a promising treatment – to an effective one. The study is being conducted in cooperation with the Sheba Medical Center.